Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by robinee3on May 27, 2011 2:31pm
239 Views
Post# 18636142

RE: RE: Profit seulement en 2013

RE: RE: Profit seulement en 2013
 J'ai oublié de parlé d'un point très important.

 Lors de l'annonce des résultats du 1er quart, la compagnie a annoncé des liquidités pour environ 56 millions.
 Étant donné que les profits seront nulle d'ici fin 2012 et que les dépenses de l'entreprise sont d'environ 7.5 millions par trimestre, il restera environ seulement une dizaine de millions dans l'encaisse à la fin de 2012.
Donc, il presque certain qu'une nouvelle émission d'action aura lieu d'ici la fin de l'année 2012. Si les redevances sont faible au cours des prochains mois, cette émission se fera à rabais. Dans mon livre à moi, l'émission d'action canceller cette hiver est tous simplement remi à plus tard.  

 Vos commentaire sont les bienvenue.

 Robinee3   
Bullboard Posts